Last 7 days
-2.2%
Last 30 days
4.6%
Last 90 days
39.0%
Trailing 12 Months
21.1%
Income Statement (Last 12 Months) | ||||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | 9.1% | 2,708,211,000 | 2,481,323,000 | 2,245,078,000 | 2,073,900,000 | 1,833,559,000 |
Operating Expenses | 9.6% | 2,828,642,000 | 2,580,509,000 | 2,350,347,000 | 2,456,480,000 | 2,227,511,000 |
S&GA Expenses | 10.8% | 218,945,000 | 197,578,000 | 192,241,000 | 457,878,000 | 455,821,000 |
EBITDA | 2.7% | -87,392,000 | -89,852,000 | -96,313,000 | -371,657,000 | - |
EBITDA Margin | 10.9% | -0.03 | -0.04 | -0.04 | -0.18 | - |
Earnings Before Taxes | 1.2% | -105,689,000 | -106,994,000 | -113,787,000 | -390,223,000 | -404,598,000 |
EBT Margin | 9.5% | -0.04 | -0.04 | -0.05 | -0.19 | - |
Interest Expenses | 23.8% | 4,525,000 | 3,656,000 | 3,523,000 | 4,076,000 | 6,146,000 |
Net Income | 0.2% | -106,553,000 | -106,808,000 | -111,983,000 | -390,179,000 | -406,487,000 |
Net Income Margin | 8.6% | -0.04 | -0.04 | -0.05 | -0.19 | - |
Free Cahsflow | -0.8% | -146,234,000 | -145,083,000 | -165,958,000 | -140,999,000 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | -9.2% | 1,697 | 1,870 | 1,841 | 1,855 | 1,586 |
Current Assets | -11.2% | 1,451 | 1,634 | 1,601 | 1,628 | 1,367 |
Cash Equivalents | -7.9% | 508 | 551 | 669 | 1,022 | 1,040 |
Net PPE | 11.8% | 20.00 | 18.00 | 16.00 | 13.00 | 9.00 |
Goodwill | 0% | 42.00 | 42.00 | 42.00 | 42.00 | 42.00 |
Liabilities | -16.3% | 657 | 785 | 737 | 744 | 495 |
Current Liabilities | -18.7% | 535 | 658 | 605 | 610 | 357 |
Long Term Debt | - | 49.00 | - | - | - | - |
LT Debt, Current | 0% | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
LT Debt, Non Current | -3.1% | 38.00 | 40.00 | 41.00 | 42.00 | 43.00 |
Shareholder's Equity | -4.2% | 1,041 | 1,086 | 1,103 | 1,111 | 1,092 |
Retained Earnings | -5.6% | -1,064 | -1,007 | -977 | -956 | -957 |
Additional Paid-In Capital | 0.6% | 2,107 | 2,095 | 2,076 | 2,064 | 2,046 |
Accumulated Depreciation | -12.4% | 8.00 | 9.00 | 8.00 | - | - |
Shares Outstanding | 0.2% | 412 | 412 | 408 | 406 | 400 |
Minority Interest | -15.7% | -0.61 | -0.53 | -0.46 | -0.37 | -0.30 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | -0.8% | -130 | -129 | -151 | -130 | -148 |
Share Based Compensation | 24.2% | 28.00 | 23.00 | 27.00 | 295 | 292 |
Cashflow From Investing | -1.2% | -444 | -439 | -319 | -90.30 | -90.51 |
Cashflow From Financing | -24.9% | 28.00 | 37.00 | 29.00 | 1,138 | 1,154 |
Buy Backs | - | 0.00 | - | - | - | - |
87.1%
78.2%
75.3%
Y-axis is the maximum loss one would have experienced if agilon health was unfortunately bought at previous high price.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -0.05 | -173,110 | 383,890 | -% |
2023-03-06 | Rockefeller Capital Management L.P. | reduced | -97.19 | -18,000 | - | -% |
2023-02-28 | Voya Investment Management LLC | added | - | -544,663 | 1,207,340 | -% |
2023-02-27 | Parallax Volatility Advisers, L.P. | reduced | -99.39 | -727,933 | 3,067 | -% |
2023-02-24 | NATIXIS | sold off | -100 | -812,000 | - | -% |
2023-02-21 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | new | - | 32.00 | 32.00 | -% |
2023-02-21 | MACQUARIE GROUP LTD | sold off | -100 | -144,000 | - | -% |
2023-02-15 | ALLIANCEBERNSTEIN L.P. | reduced | -32.17 | -1,347,150 | 1,182,850 | -% |
2023-02-15 | JANE STREET GROUP, LLC | new | - | 2,023,880 | 2,023,880 | -% |
2023-02-15 | PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | added | 2.14 | -658,000 | 1,564,000 | 0.01% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Mar 10, 2023 | capital world investors | 10.3% | 42,425,420 | SC 13G/A | |
Feb 13, 2023 | capital world investors | 9.2% | 37,918,473 | SC 13G/A | |
Feb 08, 2023 | morgan stanley | 9.1% | 37,574,546 | SC 13G/A | |
Feb 06, 2023 | wellington management group llp | 5.52% | 22,745,297 | SC 13G | |
Jan 10, 2023 | fmr llc | - | 0 | SC 13G/A | |
Feb 14, 2022 | cd&r vector holdings, l.p. | 52.3% | 205,948,808 | SC 13G | |
Feb 11, 2022 | capital world investors | 9.1% | 35,865,953 | SC 13G | |
Feb 09, 2022 | fmr llc | - | 0 | SC 13G |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | 1.75 -93.29% | 3.10 -88.11% | 7.55 -71.05% | 15.49 -40.61% | 31.29 19.98% |
Current Inflation | 1.65 -93.67% | 2.86 -89.03% | 6.74 -74.16% | 13.57 -47.97% | 27.08 3.83% |
Very High Inflation | 1.53 -94.13% | 2.57 -90.15% | 5.79 -77.80% | 11.33 -56.56% | 22.21 -14.84% |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 10, 2023 | SC 13G/A | Major Ownership Report | |
Mar 09, 2023 | 4 | Insider Trading | |
Mar 01, 2023 | 10-K | Annual Report | |
Mar 01, 2023 | 8-K | Current Report | |
Feb 22, 2023 | 8-K | Current Report | |
Feb 22, 2023 | 4 | Insider Trading | |
Feb 22, 2023 | 3 | Insider Trading | |
Feb 16, 2023 | 4 | Insider Trading | |
Feb 16, 2023 | 4 | Insider Trading | |
Feb 13, 2023 | SC 13G/A | Major Ownership Report |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-08 | Kornitzer Benjamin | acquired | 72,765 | 8.99 | 8,094 | chief med. & quality officer |
2023-03-08 | Kornitzer Benjamin | sold | -197,821 | 24.4404 | -8,094 | chief med. & quality officer |
2023-03-07 | Kornitzer Benjamin | sold | -197,197 | 24.3634 | -8,094 | chief med. & quality officer |
2023-03-07 | Kornitzer Benjamin | acquired | 72,765 | 8.99 | 8,094 | chief med. & quality officer |
2023-02-17 | MCKENZIE DIANA | acquired | - | - | 1,078 | - |
2023-02-15 | Shaker Benjamin | acquired | 28,555 | 1.00 | 28,555 | chief markets officer |
2023-02-15 | Shaker Benjamin | sold | -667,342 | 23.3704 | -28,555 | chief markets officer |
2023-02-15 | Kornitzer Benjamin | acquired | 72,765 | 8.99 | 8,094 | chief med. & quality officer |
2023-02-15 | Kornitzer Benjamin | sold | -186,028 | 22.9834 | -8,094 | chief med. & quality officer |
2023-02-14 | Kornitzer Benjamin | sold | -594,877 | 22.9851 | -25,881 | chief med. & quality officer |
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Revenues: | |||
Total revenues | $ 2,708,211 | $ 1,833,559 | $ 1,218,333 |
Expenses: | |||
Medical services expense | 2,399,798 | 1,647,659 | 1,021,877 |
Other medical expenses | 196,127 | 109,487 | 102,306 |
General and administrative | 218,945 | 455,821 | 137,292 |
Depreciation and amortization | 13,772 | 14,544 | 13,531 |
Total expenses | 2,828,642 | 2,227,511 | 1,275,006 |
Income (loss) from operations | (120,431) | (393,952) | (56,673) |
Other income (expense): | |||
Other income (expense), net | 24,725 | (4,500) | 2,465 |
Gain (loss) on lease terminations | (5,458) | 0 | 0 |
Interest expense | (4,525) | (6,146) | (8,135) |
Income (loss) before income taxes | (105,689) | (404,598) | (62,343) |
Income tax benefit (expense) | (1,640) | (886) | (865) |
Income (loss) from continuing operations | (107,329) | (405,484) | (63,208) |
Discontinued operations: | |||
Income (loss) before impairments, gain (loss) on sales and income taxes | 491 | (3,463) | (20,049) |
Gain (loss) on sales of assets, net | 0 | 473 | 20,401 |
Income tax benefit (expense) | (26) | 1,687 | 2,804 |
Total discontinued operations | 465 | (1,303) | 3,156 |
Net income (loss) | (106,864) | (406,787) | (60,052) |
Noncontrolling interests' share in (earnings) loss | 311 | 300 | 0 |
Net income (loss) attributable to common shares | $ (106,553) | $ (406,487) | $ (60,052) |
Net income (loss) per common share, basic and diluted | |||
Net income (loss) per common share from continuing operations basic and diluted | $ (0.26) | $ (1.09) | $ (0.20) |
Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share | 0 | 0 | 0.01 |
Income (Loss) from Continuing Operations, Per Diluted Share | (0.26) | (1.09) | (0.20) |
Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share | $ 0 | $ 0 | $ 0.01 |
Weighted Average Number of Shares Outstanding, Basic | 408,154 | 372,931 | 323,462 |
Weighted Average Number of Shares Outstanding, Diluted | 408,154 | 372,931 | 323,462 |
Medical Services Revenue | |||
Revenues: | |||
Total revenues | $ 2,704,396 | $ 1,829,735 | $ 1,214,270 |
Other Operating Revenue | |||
Revenues: | |||
Total revenues | $ 3,815 | $ 3,824 | $ 4,063 |
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 497,070 | $ 1,040,039 |
Restricted cash and equivalents | 10,610 | 14,781 |
Marketable securities | 411,901 | 0 |
Receivables, net | 497,574 | 293,407 |
Prepaid expenses and other current assets, net | 34,119 | 18,968 |
Total current assets | 1,451,274 | 1,367,195 |
Property and equipment, net | 20,050 | 9,161 |
Intangible assets, net | 67,680 | 55,398 |
Goodwill | 41,540 | 41,540 |
Other assets, net | 116,924 | 112,958 |
Total assets | 1,697,468 | 1,586,252 |
Current liabilities: | ||
Medical claims and related payables | 346,727 | 239,014 |
Accounts payable and accrued expenses | 183,364 | 112,946 |
Current portion of long-term debt | 5,000 | 5,000 |
Total current liabilities | 535,091 | 356,960 |
Long-term debt, net of current portion | 38,482 | 43,401 |
Other liabilities | 83,286 | 94,295 |
Total liabilities | 656,859 | 494,656 |
Commitments and contingencies | ||
Stockholders' equity (deficit): | ||
Common stock, $0.01 par value: 2,000,000 shares authorized; 412,385 and 400,095 shares issued and outstanding, respectively | 4,124 | 4,001 |
Additional paid-in capital | 2,106,886 | 2,045,572 |
Accumulated deficit | (1,064,230) | (957,677) |
Accumulated other comprehensive income (loss) | (5,560) | 0 |
Total agilon health, inc. stockholders' equity (deficit) | 1,041,220 | 1,091,896 |
Noncontrolling interests | (611) | (300) |
Total stockholders’ equity (deficit) | 1,040,609 | 1,091,596 |
Total liabilities and stockholders' equity (deficit) | $ 1,697,468 | $ 1,586,252 |